UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib

Scientific reports, 2022-07, Vol.12 (1), p.12501-12501, Article 12501

2022

Volltextzugriff (PDF)

Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies

Pigment cell and melanoma research, 2012-11, Vol.25 (6), p.819-831

2012

Volltextzugriff (PDF)

A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

PloS one, 2012-06, Vol.7 (6), p.e39653

2012

Volltextzugriff (PDF)

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

PloS one, 2013-06, Vol.8 (6), p.e67258-e67258

2013

Volltextzugriff (PDF)

The PI3K Pathway in Human Disease

Cell, 2017-08, Vol.170 (4), p.605-635

2017

Volltextzugriff (PDF)

Paxillin LD4 Motif Binds PAK and PIX through a Novel 95-kD Ankyrin Repeat, ARF-GAP Protein: A Role in Cytoskeletal Remodeling

The Journal of cell biology, 1999-05, Vol.145 (4), p.851-863

1999

Volltextzugriff (PDF)

The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338

Nature (London), 1998-11, Vol.396 (6707), p.180-183

1998

Volltextzugriff (PDF)

Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells

Current biology, 1997-03, Vol.7 (3), p.202-210

1997

Volltextzugriff (PDF)

PAK3 mutation in nonsyndromic X-linked mental retardation

Nature genetics, 1998-09, Vol.20 (1), p.25-30

1998

Volltextzugriff (PDF)

A Novel Regulator of p21-activated Kinases

The Journal of biological chemistry, 1998-09, Vol.273 (37), p.23633-23636

1998

Volltextzugriff (PDF)

Cdc42 and PAK-mediated Signaling Leads to Jun Kinase and p38 Mitogen-activated Protein Kinase Activation

The Journal of biological chemistry, 1995-11, Vol.270 (47), p.27995-27998

1995

Volltextzugriff (PDF)

A Tyrosine-phosphorylated Protein That Binds to an Important Regulatory Region on the Cool Family of p21-activated Kinase-binding Proteins

The Journal of biological chemistry, 1999-08, Vol.274 (32), p.22393-22400

1999

Volltextzugriff (PDF)

Cytoskeletal Reorganization by G Protein-Coupled Receptors Is Dependent on Phosphoinositide 3-Kinase γ, a Rac Guanosine Exchange Factor, and Rac

Molecular and Cellular Biology, 1998-08, Vol.18 (8), p.4744-4751

1998

Volltextzugriff (PDF)

The Dbl-related Protein, Lfc, Localizes to Microtubules and Mediates the Activation of Rac Signaling Pathways in Cells

The Journal of biological chemistry, 1999-01, Vol.274 (4), p.2279-2285

1999

Volltextzugriff (PDF)

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2189-2199

2011

Volltextzugriff (PDF)

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Journal of medicinal chemistry, 2021-01, Vol.64 (1), p.644-661

2021

Volltextzugriff (PDF)

Abstract B25: Development of a nanoparticle containing the PI3K/mTOR dual Inhibitor, gedatolisib, for cancer therapy

Molecular cancer research, 2020-10, Vol.18 (10_Supplement), p.B25-B25

2020

Volltextzugriff (PDF)

Requirement of p21-activated kinase (PAK) for Salmonella typhimurium-induced nuclear responses

The Journal of experimental medicine, 1999-05, Vol.189 (9), p.1479-1488

1999

Volltextzugriff (PDF)

Purified maturation promoting factor phosphorylates pp60c-src at the sites phosphorylated during fibroblast mitosis

Cell, 1989-06, Vol.57 (5), p.763-774

1989

Volltextzugriff (PDF)

PAK to the future

Trends in Cell Biology, 1999-09, Vol.9 (9), p.350-355

1999

Volltextzugriff (PDF)

A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation

PloS one, 2012, Vol.7 (6), p.e39653-e39653

2012

Volltextzugriff (PDF)

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series

Bioorganic & medicinal chemistry letters, 2013-05, Vol.23 (9), p.2787-2792

2013

Volltextzugriff (PDF)

Leveraging model-based study designs and serial micro-sampling techniques to understand the oral pharmacokinetics of the potent LTB4 inhibitor, CP-105696, for mouse pharmacology studies

Xenobiotica, 2017-07, Vol.47 (7), p.600-606

2017

Volltextzugriff (PDF)

Differential localization patterns of myristoylated and nonmyristoylated c-Src proteins in interphase and mitotic c-Src overexpresser cells

Journal of cell science, 1993-07, Vol.105 (3), p.613-628

1993

Volltextzugriff (PDF)

Abstract 3224: Preclinical PKPD modeling and human dose projection of PF-04691502, a PI3K/mTOR dual inhibitor

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3224-3224

2010

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(65)
Dissertationen
(1)

Sprache

Englisch
(66)
Japanisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib

Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies

A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

The PI3K Pathway in Human Disease

Paxillin LD4 Motif Binds PAK and PIX through a Novel 95-kD Ankyrin Repeat, ARF-GAP Protein: A Role in Cytoskeletal Remodeling

The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338

Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells

PAK3 mutation in nonsyndromic X-linked mental retardation

A Novel Regulator of p21-activated Kinases

Cdc42 and PAK-mediated Signaling Leads to Jun Kinase and p38 Mitogen-activated Protein Kinase Activation

A Tyrosine-phosphorylated Protein That Binds to an Important Regulatory Region on the Cool Family of p21-activated Kinase-binding Proteins

Cytoskeletal Reorganization by G Protein-Coupled Receptors Is Dependent on Phosphoinositide 3-Kinase γ, a Rac Guanosine Exchange Factor, and Rac

The Dbl-related Protein, Lfc, Localizes to Microtubules and Mediates the Activation of Rac Signaling Pathways in Cells

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Abstract B25: Development of a nanoparticle containing the PI3K/mTOR dual Inhibitor, gedatolisib, for cancer therapy

Requirement of p21-activated kinase (PAK) for Salmonella typhimurium-induced nuclear responses

Purified maturation promoting factor phosphorylates pp60c-src at the sites phosphorylated during fibroblast mitosis

PAK to the future

A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series

Leveraging model-based study designs and serial micro-sampling techniques to understand the oral pharmacokinetics of the potent LTB4 inhibitor, CP-105696, for mouse pharmacology studies

Differential localization patterns of myristoylated and nonmyristoylated c-Src proteins in interphase and mitotic c-Src overexpresser cells

Abstract 3224: Preclinical PKPD modeling and human dose projection of PF-04691502, a PI3K/mTOR dual inhibitor

Suchergebnisse filtern